US EditionInnovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China
- The FRUSICA-2 clinical trial has shown that sintilimab and fruquintinib together improve progression-free survival in advanced renal cell carcinoma in China, as assessed by blinded independent central review.
- The combination of sintilimab and fruquintinib met its primary endpoint of progression-free survival in advanced renal cell carcinoma, as reported by Innovent and HUTCHMED.
- Key study results showed a 60.0% objective response rate and an 85.0% disease control rate in patients treated with the sintilimab and fruquintinib combination.
- Prof Dingwei Ye stated that targeted therapies have significantly evolved the treatment landscape for advanced renal cell carcinoma, reflecting advancements in patient care.
Insights by Ground AI
Does this summary seem wrong?
25 Articles
25 Articles
All
Left
2
Center
6
Right
Times-News+19 Reposted by 19 other sources
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China
SAN FRANCISCO and SUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…
·Twin Falls, United States
Read Full Article
Coverage Details
Total News Sources25
Leaning Left2Leaning Right0Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
